Research Articles | Page 4 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Research Articles

  1. Home
  2. Research

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
A growing panoply of options for patients with paroxysmal nocturnal hemoglobinuria Sep 2024 American Journal of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria Sep 2024 American Journal of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition Sep 2024 American Journal of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial Sep 2024 The Lancet Haematology Myelodysplastic Syndromes (MDS)
Advances in the management of higher-risk myelodysplastic syndromes: future prospects Sep 2024 Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
A growing panoply of options for patients with paroxysmal nocturnal hemoglobinuria Sep 2024 American Journal of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Clinical Outcomes and Healthcare Resource Utilization for Patients With Lower-Risk Myelodysplastic Syndromes Treated With Erythropoiesis-Stimulating Agents Sep 2024 Clinical Lymphoma, Myeloma & Leukemia Myelodysplastic Syndromes (MDS)
SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes Sep 2024 Clinical Lymphoma, Myeloma & Leukemia Myelodysplastic Syndromes (MDS)
Allogeneic Hematopoietic Cell Transplantation for the Treatment of Severe Aplastic Anemia: Evidence-Based Guidelines From the American Society for Transplantation and Cellular Therapy Sep 2024 Transplantation and Cellular Therapy Myelodysplastic Syndromes (MDS)
Oral complement factor D inhibitor danicopan for paroxysmal nocturnal hemoglobinuria Sep 2024 Expert Review of Clinical Pharmacology Paroxysmal Nocturnal Hemoglobinuria (PNH)